VRCA Verrica Pharmaceuticals Inc.

Nasdaq Pharmaceutical Preparations DE CIK: 0001660334
AI RATING
HOLD
58% Confidence

Investment Thesis

Verrica demonstrates impressive revenue growth of 370% YoY and maintains a solid cash position with zero long-term debt, indicating near-term financial viability. However, the company is deeply unprofitable with operating losses of $9.7M on just $5M revenue and negative free cash flow of $9.2M, providing limited runway without demonstrated progress toward profitability or achievement of major commercialization milestones.

Strengths

  • + Strong top-line revenue growth of 370% YoY demonstrates early market traction and product acceptance
  • + Solid cash position of $20.6M representing 53% of total assets with zero long-term debt reduces financial distress risk
  • + Healthy liquidity ratios (current 2.10x, quick 1.98x) provide adequate short-term financial flexibility

Risks

  • ! Deeply unprofitable with operating losses of $9.7M exceeding revenue of $5M by 194%, indicating unsustainable unit economics
  • ! Negative free cash flow of $9.2M with approximately 2 years of cash runway at current burn rate without profitability inflection
  • ! Very small absolute revenue base from nascent commercialization makes path to sustainable profitability unclear and subject to execution risk

Key Metrics to Watch

Financial Metrics

Revenue
5.0M
Net Income
-9.7M
EPS (Diluted)
$-0.45
Free Cash Flow
-9.2M
Total Assets
38.8M
Cash
20.6M

Profitability Ratios

Gross Margin N/A
Operating Margin -193.4%
Net Margin -192.8%
ROE -60.3%
ROA -25.0%
FCF Margin -182.4%

Balance Sheet & Liquidity

Current Ratio
2.10x
Quick Ratio
1.98x
Debt/Equity
0.00x
Debt/Assets
58.6%
Interest Coverage
-2.07x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-14T09:29:00.915310 | Data as of: 2026-03-31 | Powered by Claude AI